Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data

Autor: Jagannath, Sundar, Berdeja, Jesus, Rifkin, Robert, Cole, Craig, Thompson, Michael A., Ricafort, Rosanna J., Scofield, Amanda, Mohamed, Hesham, Sy, Oumar, Vij, Ravi, Bensinger, William
Zdroj: In Clinical Lymphoma Myeloma and Leukemia September 2017 17 Supplement 2:S330-S331
Databáze: ScienceDirect
Externí odkaz: